APA (7th ed.) Citation

Papadopoulos, K., Fu, S., Hamilton, E., Spira, A., Scott, L., Wang, J., . . . Hamid, O. (2022). 750 TWT-101: A first-in-clinic, phase 1/2 study of CFI-402411, a hematopoietic progenitor kinase-1 (HPK1) inhibitor, as a single agent and in combination with pembrolizumab in subjects with advanced solid malignancies. Journal for immunotherapy of cancer, 10(Suppl 2), A783. https://doi.org/10.1136/jitc-2022-SITC2022.0750

Chicago Style (17th ed.) Citation

Papadopoulos, Kyriakos, et al. "750 TWT-101: A First-in-clinic, Phase 1/2 Study of CFI-402411, a Hematopoietic Progenitor Kinase-1 (HPK1) Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Malignancies." Journal for Immunotherapy of Cancer 10, no. Suppl 2 (2022): A783. https://doi.org/10.1136/jitc-2022-SITC2022.0750.

MLA (9th ed.) Citation

Papadopoulos, Kyriakos, et al. "750 TWT-101: A First-in-clinic, Phase 1/2 Study of CFI-402411, a Hematopoietic Progenitor Kinase-1 (HPK1) Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Malignancies." Journal for Immunotherapy of Cancer, vol. 10, no. Suppl 2, 2022, p. A783, https://doi.org/10.1136/jitc-2022-SITC2022.0750.